RxDoctor Payments DataLook up a doctor →

Daniel Citron, MD

Endocrinology, Diabetes & Metabolism · Denver, CONPI 1861442410

Payments from drug & device makers

$8,074in general payments, 2019–2025

Across 431 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$618
  • GSK$617
  • Lilly USA, LLC$563
  • AstraZeneca$507
  • Astellas Pharma US Inc$456
  • plus $3K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)90$1,895
Novo Nordisk36$618
GSK35$617
Lilly USA, LLC34$563
AstraZeneca(2 entities)29$507
Astellas Pharma US Inc16$456
Pfizer22$411
Johnson & Johnson25$380
Amgen(2 entities)18$343
Esperion Therapeutics, Inc.17$287
Merck15$230
Novartis9$221
Boehringer Ingelheim10$185
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$137
Idorsia Pharmaceuticals US Inc7$115
Kowa Pharmaceuticals America, Inc.6$95
Ironwood Pharmaceuticals, Inc4$87
Bayer4$72
Sumitomo Pharma America, Inc.3$67
Amarin Pharma, Inc.3$66
IBSA Pharma Inc.4$64
Eisai Inc.2$38
Exact Sciences2$36
Grifols USA, LLC2$36
Dexcom, Inc.1$36
Therapeuticsmd, Inc.2$34
Sunovion Pharmaceuticals Inc.2$27
ANI Pharmaceuticals, Inc.1$25
Takeda Pharmaceuticals U.S.A., Inc.1$25
Inspire Medical Systems, Inc.1$23
Electromed, Inc.1$23
Radius Health, Inc.1$22
Fresenius Kabi USA, LLC1$21
Jazz Pharmaceuticals Inc.1$21
Ultragenyx Pharmaceutical Inc.1$21
Neuronetics, Inc.1$19
Nestle Healthcare Nutrition Inc.1$15
Hologic Sales And Service, LLC1$14
Dynavax Technologies Corporation1$13
Acerus Pharmaceuticals Corporation1$13
Teva Pharmaceuticals USA, Inc.1$11
Hikma Pharmaceuticals USA1$11

How this compares

$8,074 in reported general payments places this provider in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado →

Medicare billing

Part B allowed, 2024
$223,159
Medicare patients
518
Services billed
2,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Denver

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →